

Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy

Summary for clinicians

This is a summary of the American Academy of Neurology (AAN) Evidence in Focus, “Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy” which was published online in *Neurology*® on May 14, 2025.

An AAN Evidence in Focus is a type of systematic review that uses an abbreviated version of the AAN guideline methodology to highlight the strength of evidence underlying new therapies and facilitate discussion concerning their appropriate use. This process does not generate specific recommendations for care. The accompanying discussion is intended to aid the practicing neurologist, other medical professionals, patients, and families in interpreting the published data to inform clinical decision making.

Please refer to the full Evidence in Focus at [AAN.com/guidelines](https://www.aan.com/guidelines) for more information, including a detailed review of the evidence and additional clinical considerations for the use of delandistrogene moxeparvovec.

Evidence in Focus Scope

This Evidence in Focus reviews the current evidence on the efficacy and adverse effects of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) and presents clinical considerations regarding use. Delandistrogene moxeparvovec (trade name Elevidys) is a single-dose gene transfer therapy approved for the treatment of DMD. This type of gene therapy delivers (using an adeno-associated virus) a truncated version of the *DMD* gene (“microdystrophin”) to attempt to restore partial function to the gene.

Summary of Evidence

Six clinical trials evaluating the motor function and safety data of delandistrogene moxeparvovec were identified, of which four had peer-reviewed data available. From the four studies with available data (two Class I and two Class III), exposure data is available on 134 boys aged ≥4 to <8 years, of which 128 are ambulatory. Data is not available for individuals outside of this age range.

Summary of Conclusions

Both Class I studies failed to meet the primary functional motor outcome as assessed by change in the North Star Ambulatory Assessment score. Several secondary functional motor outcomes demonstrated improvement in the treatment group with small effect sizes, not meeting statistical significance from hierarchical analysis. Corticosteroid dose exposure was higher in the treatment group in the first 12 weeks post-infusion, potentially contributing to measured differences between groups. Safety outcomes were similar across studies with multiple treatment-related adverse events, including peri-infusion effects, immune myositis and myocarditis, thrombocytopenia, and liver toxicity. No deaths or permanent organ failure were associated with the treatment in the clinical trials; however, a first death has been reported in clinical practice.



Key Considerations for Use

Despite not demonstrating efficacy in its primary outcome, delandistrogene moxeparvovec has been approved by the US Food and Drug Administration (FDA) for use in boys with DMD. This decision was supported by the relative safety of the product and small improvement signals in the secondary outcome measures in the phase 3 clinical trial. As the drug may now be actively prescribed in the US and other countries, providers should be aware of the limitations of the treatment and the need to monitor and counsel patients for immune-related side effects including myositis, myocarditis, thrombocytopenia, liver injury, and death, which may require expanded clinical infrastructure.

Suggestions for Future Research

Additional clinical trials and careful collection of real-world evidence from treated patients will be essential to establish short- and long-term effectiveness and inform understanding of benefits and risks of delandistrogene moxeparvovec across the lifespan.

Clinical practice guidelines, practice advisories, systematic reviews, Evidence in Focus articles, and other guidance published by the American Academy of Neurology and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments or methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; (5) represents the medical/scientific opinion of the author panel based on an analysis of then-current clinical data, literature, and public comment (where applicable); and (6) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. The AAN provides this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. The AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. The AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. Physicians are encouraged to read the full Evidence in Focus so they understand all evidence and context associated with the conclusions presented in this summary.

The AAN develops these summaries as educational tools for neurologists, patients, family members, caregivers, and the public. You may download and retain a single copy for your personal use. Please contact guidelines@aan.com to learn about options for sharing this content beyond your personal use.

American Academy of Neurology, 201 Chicago Avenue, Minneapolis, MN 55415

Copies of this summary and additional companion tools are available at AAN.com/guidelines or through AAN Member Services at (800) 879-1960.

© 2025 American Academy of Neurology

